Skip to content

Evaluation of Sinetrol® Xpur in Fat Mass Reduction on Overweight and Obese Subjects

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04149158
Enrollment
77
Registered
2019-11-04
Start date
2015-04-30
Completion date
2017-09-30
Last updated
2019-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Change in Total Body Fat Mass Percentage Loss Versus Body Weight

Brief summary

This study aims to evaluate effects of a 16-week supplementation with a polyphenol rich extract, Sinetrol® Xpur, on fat mass accumulation and body weight management improvement.Subjects were overweight or obese and received polyphenol supplement or placebo. A 4-week follow-up as performed to evaluate its effect after supplementation stop.

Interventions

DIETARY_SUPPLEMENTPlacebo
DIETARY_SUPPLEMENTSinetrol® Xpur

Sponsors

Fytexia
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
25 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* overweight or obese (25 kg.m-2\<BMI\<42.5kg.m-2) * healthy

Exclusion criteria

* metabolic or chronical disease with treatments (i.e.: diabetes, dyslipidemia, thyroiditis, inflammatory disease, immunological disease, infectious disease, asthma, anxiety and depression) * food allergy to the ingredients of the product (grapefruit, orange, caffeine, guarana) * involved in the prior 6 months in a chronic treatment program, eating disorders history, subjected to weight reduction by surgery * start or quit smoking, high alcohol consumption * pregnant, breastfeeding, wanting to have a baby, * menopausal women

Design outcomes

Primary

MeasureTime frame
Change in total body fat percentage loss versus bodyweightweek1; week16; week20

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026